CEO Of Institute For OneWorld Health Advocates Focus First On Developing World Markets

New biotech processes are poised to change the economics of manufacturing drugs, creating the potential for delivering both affordable medicines to patients in the developing world and laying the foundation for new markets, according to Victoria Hale, Ph.D., CEO of the Institute for OneWorld Health. The founder of the first nonprofit pharmaceutical company in the U.S. spoke yesterday on a panel, "Synthetic Biology at the Edge" at the 8th International Biotech Summit in Berkeley.